Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 3, randomised, double-blind trial of dienogest in Heavy menstrual bleeding, sponsored by Bayer. Primary endpoint: Absolute change in Menstrual Blood Loss at 90 days. Started Jun 2012; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Women 18 years or older in generally good health with a diagnosis of heavy menstrual bleeding without organic pathology, requesting contraception, with a BMI <= 32.
04
Endpoints
Primary
Absolute change in Menstrual Blood Loss
Beyond the preview
Go deeper on NCT01638923.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01638923.